DGCI Clinical Trial to Oxford

DGCI approves Phase IIIII clinical trials of Oxford University vaccine by Serum Institute, Pune

The Drugs Controller General of India has given approval to Serum Institute of India, Pune to conduct Phase IIIII clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.

This will hasten the development of the COVID-19 vaccine. Union Health Ministry said, India continues to improve the Case Fatality Rate (CFR), and maintain its global position of having one of the lowest COVID fatalities rates.

With a further fall, the current CFR touched 2.11 per cent today.

The management strategy of COVID-19 also focuses on early detection and isolation of cases with seamless patient management and prioritising care of the high-risk population, leading to increase in recoveries across the country.

The Ministry said, India has seen more than 40,574 patients recovered in the last 24 hours.

This takes the total recoveries to 11,86,203 and recovery rate to 65.77 per cent amongst COVID-19 patients.

With improving daily recovery number, the gap between the recovered cases and the active cases has increased to more than 6 lakh.
The actual active case load is over 5,79,000 and all are under medical supervision.

Published by Naresh Sagar

Mentor MSME, Motivator, Media Event Org, Management fiscal & Water management.Social Media branding,Internet broadcasters,Propunder of Indian Philosophy

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: